Lanreotide In Polycystic Kidney Disease Study

NCT02127437 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

159

Enrollment

OTHER

Sponsor class

Conditions

Autosomal Dominant Polycystic Kidney Disease (ADPKD

Interventions

DRUG: Lanreotide
DRUG: saline

Sponsor

Assistance Publique - Hôpitaux de Paris

Collaborators

[object Object]
[object Object]